ICD Research's Enzon Pharmaceuticals, Inc. : Pharmaceuticals and Healthcare - Company Profile, SWOT & Financial Report contains in depth information and data about the company and its operations. The profile contains a company overview, key facts,major products and services, swot analysis, business description, company history, financial analysis, key employees, company locations and subsidiaries, employee biographies as well as competitive benchmarking data.
This report is a crucial resource for industry executives and anyone looking to access key information about Enzon Pharmaceuticals, Inc.
The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.
Examines and identifies key information and issues about Enzon Pharmaceuticals, Inc. for business intelligence requirements.
Studies and presents the company's strengths, weaknesses, opportunities (growth potential) and threats (competition). Strategic and operational business information is objectively reported.
Provides data on company financial performance and competitive benchmarking.
The profile also contains information on business operations, company history, major products and services, key employees, locations and subsidiaries.
Reasons To Buy
Quickly enhance your understanding of Enzon Pharmaceuticals, Inc.
Gain insight into the marketplace and a better understanding of internal and external factors which could impact the industry.
Increase business/sales activities by understanding your competitors’ businesses better.
Recognize potential partnerships and suppliers.
Enzon Pharmaceuticals, Inc. (Enzon) is a biopharmaceutical company, based in the US. The company primarily focuses on research and development of innovative therapeutics for cancer patients. The company primarily operates through Customized Linker Technology and Locked Nucleic Acid (LNA) technology. Enzon has four compounds in clinical development which include a PEGylated version of the active metabolite of the cancer drug, irinotecan, PEG-SN38, and mRNA antagonists targeting Hypoxia-Inducible Factor-1? (HIF-1?), Survivin and the Androgen Receptor (AR). The company has novel mRNA in preclinical research stage. Additionally, Enzon receives royalty revenues from licensing arrangements with other companies related to sales of products developed using its proprietary Customized Linker Technology comprising PEGINTRON, Macugen, Sylatron, CIMZIA, Oncaspar and Adagen. Enzon is headquartered in Piscataway, New Jersey, the US.